Short Interest in Evotec SE (NASDAQ:EVO) Grows By 42.0%

Evotec SE (NASDAQ:EVO) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 271,800 shares, a growth of 42.0% from the August 31st total of 191,400 shares. Based on an average daily trading volume, of 83,900 shares, the short-interest ratio is presently 3.2 days. Approximately 0.1% of the shares of the company are short sold.

Evotec Trading Up 2.3 %

NASDAQ:EVO traded up $0.08 on Friday, hitting $3.57. 116,721 shares of the stock were exchanged, compared to its average volume of 107,509. Evotec has a 52 week low of $2.85 and a 52 week high of $12.00. The company’s 50-day moving average price is $3.68 and its 200 day moving average price is $5.02. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83.

Analyst Ratings Changes

A number of research firms have weighed in on EVO. HC Wainwright decreased their price target on shares of Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, August 15th. Deutsche Bank Aktiengesellschaft cut Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Finally, Morgan Stanley cut Evotec from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $15.00 to $6.00 in a report on Monday, July 29th.

Hedge Funds Weigh In On Evotec

Institutional investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Evotec in the 2nd quarter valued at approximately $87,000. Cetera Advisors LLC acquired a new position in shares of Evotec in the 1st quarter valued at approximately $188,000. DCF Advisers LLC grew its position in shares of Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares during the period. Optiver Holding B.V. grew its position in shares of Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the period. Finally, Mubadala Investment Co PJSC acquired a new position in shares of Evotec in the 4th quarter valued at approximately $53,931,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.